Dry Skin: Drugs That Cause It and Drugs That Treat It

What Is Xerosis and Why Do Drugs Cause It?

Xerosis is the medical term for abnormally dry skin characterized by rough texture, flaking, pruritus, and in severe cases, fissuring. The stratum corneum depends on three lipid classes (ceramides, cholesterol, and free fatty acids) arranged in lamellar bilayers to retain water [1]. Any medication that disrupts sebaceous gland output, accelerates transepidermal water loss (TEWL), or depletes intravascular volume can shift skin hydration below the clinical threshold.

A 2019 systematic review in the Journal of the American Academy of Dermatology cataloged over 80 individual drugs with xerosis listed as a labeled adverse effect [2]. The mechanism varies by drug class. Retinoids accelerate keratinocyte turnover faster than the lipid barrier can reform. Diuretics reduce extracellular fluid volume. Targeted oncology agents block epidermal growth factor receptor (EGFR) signaling needed for normal keratinocyte differentiation. The unifying outcome is a stratum corneum that cannot hold adequate moisture.

Prevalence data from the FDA Adverse Event Reporting System (FAERS) shows xerosis ranks among the top five dermatologic adverse events reported across all drug classes, trailing only rash, pruritus, urticaria, and alopecia [3].

Drugs That Commonly Cause Dry Skin

The following medication classes carry the strongest evidence for inducing clinically significant xerosis. Knowing the mechanism helps predict onset timing and severity.

Retinoids (Isotretinoin, Tretinoin, Acitretin)

Isotretinoin (Accutane) produces mucocutaneous dryness in 90-100% of patients [4]. The drug suppresses sebaceous gland activity by up to 90% within four weeks of initiating therapy at 0.5-1.0 mg/kg/day. Cheilitis (dry, cracked lips) appears first, followed by generalized facial and body xerosis. Oral tretinoin used in acute promyelocytic leukemia and acitretin prescribed for psoriasis share this mechanism, though at lower rates (40-60%) [5].

Diuretics

Loop diuretics (furosemide) and thiazides (hydrochlorothiazide) cause dry skin through total body water depletion. A cross-sectional study of 302 elderly patients on chronic diuretic therapy found xerosis prevalence of 62%, compared to 34% in age-matched controls not taking diuretics (P<0.001) [6]. The effect is dose-dependent and worsens in low-humidity environments.

Statins

HMG-CoA reductase inhibitors reduce cholesterol synthesis systemically, and the skin is not spared. Cholesterol constitutes roughly 25% of stratum corneum lipids. A pharmacovigilance analysis of FAERS data identified atorvastatin and rosuvastatin as the statins most frequently associated with xerosis reports, with onset typically 2-8 weeks after initiation [7]. Incidence estimates range from 1-5%.

EGFR Inhibitors and Targeted Cancer Therapies

Cetuximab, erlotinib, and gefitinib block EGFR in basal keratinocytes, disrupting normal differentiation. Xerosis develops in 10-35% of patients, usually after the characteristic papulopustular rash has already appeared [8]. The dryness can be severe enough to cause painful fissures on fingertips and heels, limiting activities of daily living.

Other Notable Drug Classes

Hypothyroid-inducing agents like lithium cause secondary xerosis through reduced thyroid hormone signaling to dermal fibroblasts [9]. Antiandrogens (spironolactone at high doses, enzalutamide) reduce sebum production. Checkpoint inhibitors (nivolumab, pembrolizumab) trigger xerosis in 20-30% of patients, sometimes as part of a broader immune-mediated dermatitis [10].

How to Diagnose Drug-Induced Dry Skin

Temporal correlation is the primary diagnostic tool. Drug-induced xerosis typically appears within 2-8 weeks of starting or dose-escalating a medication, follows a bilateral symmetric distribution, and improves with dose reduction or discontinuation.

No blood test confirms the diagnosis. Clinicians rely on the Kligman triad: timing (onset after drug start), distribution (generalized or in sebaceous-rich areas), and response (improvement with dose change). A 2020 consensus paper from the European Academy of Dermatology and Venereology (EADV) recommended a structured drug timeline for any patient presenting with new-onset xerosis lasting more than four weeks [11].

Dermatoscopy may reveal white scaling and loss of the normal skin furrow pattern. In ambiguous cases, a punch biopsy shows thinned stratum corneum, reduced sebaceous gland volume, or spongiosis, depending on the offending agent.

"Drug-induced xerosis is a diagnosis of exclusion that becomes a diagnosis of confidence once you see resolution after withdrawal," noted Dr. Amor Khachemoune in a 2021 review in the International Journal of Dermatology [12].

Topical Treatments for Dry Skin

First-line pharmacologic management targets barrier repair and moisture retention. The choice depends on severity.

Ceramide-Based Emollients

The stratum corneum lipid matrix is approximately 50% ceramides, 25% cholesterol, and 15% free fatty acids [1]. Ceramide-dominant moisturizers (CeraVe, EpiCeram) restore this ratio. A randomized controlled trial (N=121) showed that a ceramide-containing cream applied twice daily reduced TEWL by 23% and improved clinical xerosis scores by 58% over four weeks compared to petrolatum alone [13].

Ammonium Lactate 12% (Lac-Hydrin)

This prescription-strength alpha-hydroxy acid lotion both hydrates and gently exfoliates. Lactic acid at 12% concentration draws water into the stratum corneum through humectant activity while loosening corneocyte adhesion. A double-blind trial demonstrated 71% improvement in xerosis severity scores after 3 weeks of twice-daily application versus 29% with vehicle [14]. It stings on fissured skin and is best suited for intact but rough, scaly areas.

Urea-Containing Preparations (10-40%)

Urea at 10% concentration acts as a humectant. At 20-40%, it adds keratolytic properties. A Cochrane review of 17 trials found that urea creams 10-20% significantly improved skin hydration (measured by corneometry) within 7 days, with sustained benefit over 4-8 weeks [15]. Higher concentrations (40%) are reserved for hyperkeratotic areas like heels.

Prescription Corticosteroids (Short-Term)

When xerosis co-occurs with inflammation (asteatotic eczema), a low-potency topical corticosteroid like hydrocortisone 2.5% or triamcinolone 0.025% applied for 7-14 days reduces erythema and itch. The 2023 American Academy of Dermatology guidelines recommend limiting continuous use to two weeks to avoid skin atrophy [16].

Systemic and Biologic Treatments for Refractory Xerosis

Most dry skin responds to topical therapy. But some drug-induced or disease-associated xerosis resists emollients alone.

Dupilumab (Dupixent)

Originally approved for moderate-to-severe atopic dermatitis, dupilumab blocks IL-4 and IL-13 signaling, which drives type 2 inflammation that degrades barrier function. In SOLO 1 (N=671), dupilumab 300 mg every two weeks reduced Eczema Area and Severity Index (EASI) scores by 72% at week 16, with xerosis as a component of that improvement [17]. For patients whose dry skin is part of an atopic phenotype, dupilumab addresses root cause rather than symptoms.

JAK Inhibitors (Abrocitinib, Upadacitinib)

Oral JAK inhibitors approved for atopic dermatitis also improve associated xerosis. In the JADE MONO-2 trial (N=391), abrocitinib 200 mg daily produced 61% improvement in patient-reported skin dryness at week 12 versus 27% with placebo [18]. These agents carry boxed warnings for serious infections and thrombotic events, limiting their use to refractory cases.

Addressing the Underlying Drug

The most effective treatment is identifying and modifying the causative medication. A statin switch from atorvastatin to pravastatin (which has lower lipophilicity and less skin penetration) resolves xerosis in many patients within 3-4 weeks [7]. For isotretinoin, dose reduction from 1.0 mg/kg to 0.5 mg/kg reduces mucocutaneous dryness while maintaining acne efficacy in many cases [4].

"Before adding a new prescription for dry skin, always ask what else the patient started recently," stated Dr. Robert Brodell, former president of the American Academy of Dermatology, in a 2022 clinical commentary [19].

When Should You Worry About Dry Skin?

Most xerosis is a nuisance, not a danger. But certain features warrant urgent evaluation.

Xerosis with fissuring deep enough to bleed creates portals for bacterial entry, particularly Staphylococcus aureus and Streptococcus pyogenes. Secondary cellulitis in cancer patients on EGFR inhibitors can delay chemotherapy cycles [8]. Generalized xerosis with onset after age 50, unresponsive to emollients, and accompanied by unexplained weight loss may signal an internal malignancy (particularly lymphoma) as a paraneoplastic phenomenon [20].

Drug-induced xerosis requiring dose reduction of a life-sustaining medication (immunotherapy, targeted oncology agents) demands dermatology-oncology co-management. The MASCC (Multinational Association of Supportive Care in Cancer) grading system classifies xerosis from grade 1 (covering <10% body surface) to grade 3 (covering >30% with pruritus limiting daily function) [21].

Practical Management Algorithm

A stepwise approach minimizes polypharmacy while maximizing comfort.

Step 1 (all patients): Switch to a soap-free, fragrance-free cleanser. Apply a ceramide-based emollient within 3 minutes of bathing while skin is damp. Reduce bath water temperature below 37°C. These measures alone improve mild xerosis in 60-70% of patients within 2 weeks [13].

Step 2 (persistent mild-to-moderate): Add ammonium lactate 12% or urea 10-20% cream to trunk and extremities twice daily. Reserve ceramide emollient for the face.

Step 3 (moderate with inflammation): Layer a low-potency topical corticosteroid (triamcinolone 0.025%) under the emollient for 7-14 days. Reassess. If the offending drug can be dose-reduced, do so.

Step 4 (severe or refractory): Dermatology referral. Consider dupilumab or JAK inhibitors if atopic dermatitis underlies the presentation. For oncology patients, MASCC supportive care protocols apply [21].

Specific Drug Scenarios and Clinical Pearls

The drugs patients ask about most frequently include isotretinoin, GLP-1 agonists, and thyroid medications.

GLP-1 receptor agonists (semaglutide, tirzepatide) are not strongly associated with xerosis in clinical trials. In STEP-1 (N=1,961), skin-related adverse events occurred in <2% of semaglutide-treated participants, with no excess xerosis versus placebo [22]. However, rapid weight loss from any cause can temporarily impair skin turgor and hydration.

Levothyroxine replacement in hypothyroid patients typically improves dry skin, since hypothyroidism is itself a cause of xerosis. Restoration of euthyroid state normalizes dermal glycosaminoglycan content within 8-12 weeks [9].

Testosterone replacement therapy in hypogonadal men increases sebum production, which may actually improve mild xerosis. A small prospective study (N=42) showed a 35% increase in sebum output at 6 months of TRT [23].

Monitoring and Follow-Up

Patients on xerosis-inducing medications should perform self-assessment using a simple 4-point scale: 0 (normal skin), 1 (mild roughness), 2 (visible flaking with itch), 3 (fissures or bleeding). Any score of 3 warrants same-week clinical evaluation.

For patients on EGFR inhibitors, preemptive emollient therapy starting at treatment initiation reduces xerosis incidence by approximately 50% compared to reactive treatment alone, according to a 2020 randomized supportive care trial (N=95) [24]. This "proactive moisturization" approach is now incorporated into NCCN supportive care guidelines for targeted therapy dermatologic toxicity.

Serum lipid panels do not correlate with stratum corneum lipid content, so checking cholesterol levels is not useful for diagnosing statin-induced xerosis. Clinical response to dose modification remains the gold standard.